Subcutaneous epcoritamab monotherapy in Japanese adults with relapsed/refractory diffuse large B‐cell lymphoma

Circulating tumor DNA in B-cell lymphoma: technical advances, clinical applications, and perspectives for translational research

(2022) Eliza M. Lauer et al.   LEUKEMIA

Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of phase 3 TRANSFORM study

(2022) Jeremy S Abramson et al.   BLOOD

Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell–Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial

(2022) Catherine Thieblemont et al.   JOURNAL OF CLINICAL ONCOLOGY

A phase 2 study of polatuzumab vedotin + bendamustine + rituximab in relapsed/refractory diffuse large B‐cell lymphoma

(2021) Yasuhito Terui et al.   CANCER SCIENCE

Perspectives on outpatient administration of CAR-T cell therapy in aggressive B-cell lymphoma and acute lymphoblastic leukemia

(2021) G Doug Myers et al.   Journal for ImmunoTherapy of Cancer

Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study

(2021) Martin Hutchings et al.   LANCET

Characteristics and Clinical Outcomes of Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma Who Received At Least 3 Lines of Therapies

(2021) Mehdi Hamadani et al.   Clinical Lymphoma Myeloma & Leukemia

Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma

(2021) Michael R. Bishop et al.   NEW ENGLAND JOURNAL OF MEDICINE

Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma

(2021) Frederick L. Locke et al.   NEW ENGLAND JOURNAL OF MEDICINE

Polatuzumab vedotin plus bendamustine and rituximab in relapsed/refractory DLBCL: survival update and new extension cohort data

(2021) Laurie H. Sehn et al.   Blood Advances

DuoBody-CD3xCD20 induces potent T-cell-mediated killing of malignant B cells in preclinical models and provides opportunities for subcutaneous dosing

(2020) Patrick J. Engelberts et al.   EBioMedicine

Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study

(2020) Jeremy S Abramson et al.   LANCET

Epidemiology of malignant lymphoma and recent progress in research on adult T-cell leukemia/lymphoma in Japan

(2018) Hiroaki Miyoshi et al.   INTERNATIONAL JOURNAL OF HEMATOLOGY

ASBMT Consensus Grading for Cytokine Release Syndrome and Neurological Toxicity Associated with Immune Effector Cells

(2018) Daniel W Lee et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma

(2018) Stephen J. Schuster et al.   NEW ENGLAND JOURNAL OF MEDICINE

Epidemiology and secular trends of malignant lymphoma in Japan: Analysis of 9426 cases according to the World Health Organization classification

(2018) Reiji Muto et al.   Cancer Medicine

Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy

(2016) Bruce D. Cheson et al.   BLOOD

The 2016 revision of the World Health Organization classification of lymphoid neoplasms

(2016) S. H. Swerdlow et al.   BLOOD

Noninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencing

(2015) D. M. Kurtz et al.   BLOOD

Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification

(2014) Bruce D. Cheson et al.   JOURNAL OF CLINICAL ONCOLOGY

The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications

(2011) E. Campo et al.   BLOOD

Guidelines for the Management of Pediatric and Adult Tumor Lysis Syndrome: An Evidence-Based Review

(2008) Bertrand Coiffier et al.   JOURNAL OF CLINICAL ONCOLOGY